Intrapleural administration of OK432 in cancer patients: activation of NK cells and reduction of suppressor cells.
Twelve patients with carcinomatous pleural effusions were treated with single intrapleural (i.pl.) administration of OK432 on day 0 and the effects of i.pl. OK432 on natural killer (NK) cell activity were followed on day 7. Two patients showed no clinical evidence of therapeutic benefit from i.pl. OK432. In the other 10 patients, pleural effusions and/or tumor cells in the effusions had decreased or disappeared by day 7. NK cell activity was markedly low or absent in pleural effusions of untreated patients due to the presence of adherent effusion cells capable of suppressing the maintenance and interferon-induced augmentation of NK cell activity. I.pl. injection of OK432 resulted in enhancement of NK cell activity and abrogation of NK suppressor cell activity in the effusions. On the other hand, blood NK cell activity was not consistently altered by i.pl. OK432. In vitro treatment of effusion mononuclear cells from untreated patients with OK432, but not with interferon, augmented NK cell activity. In addition, adherent effusion cells of untreated patients lost their NK suppressor function following in vitro OK432 treatment. These results suggest that i.pl. administration of OK432 will result in augmentation of NK cell activity and reduction of NK suppressor cell activity in pleural effusions, which could be responsible for the antitumor activity of i.pl. OK432.
D000230:Adenocarcinoma / Q000150:complications / Q000628:therapy; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000628:therapy; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology*; D008175:Lung Neoplasms / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D010996:Pleural Effusion / Q000209:etiology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D001688:Biological Products; D007370:Interferon Type I; D010844:Picibanil